


# Transdermal Drug Delivery

Second Edition, Revised and Expanded



edited by  
Richard H. Guy  
Jonathan Hadgraft

Noven Pharmaceuticals, Inc.

**Library of Congress Cataloging-in-Publication Data**

A catalog record for this book is available from the Library of Congress.

**ISBN: 0-8247-0861-X**

The first edition was published as *Transdermal Drug Delivery: Developmental Issues and Research Initiatives*, edited by Jonathan Hadgraft and Richard H. Guy.

This book is printed on acid-free paper.

**Headquarters**

Marcel Dekker, Inc.  
270 Madison Avenue, New York, NY 10016  
tel: 212-696-9000; fax: 212-685-4540

**Eastern Hemisphere Distribution**

Marcel Dekker AG  
Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland  
tel: 41-61-260-6300; fax: 41-61-260-6333

**World Wide Web**

<http://www.dekker.com>

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above.

**Copyright © 2003 by Marcel Dekker, Inc. All Rights Reserved.**

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

**PRINTED IN THE UNITED STATES OF AMERICA**

Pre

The pr  
of acac  
admini  
availab  
pharm  
transde  
pended  
optima  
T  
absorpt  
nal age  
propt  
are mu  
techniq  
the bas  
transpo  
vised to  
can be  
through  
in the u  
include  
viewed  
fully ex

tion, which elicits a systemic effect. This route has a number of attractions, and an accurate and predictive model would be invaluable in the selection and evolution of appropriate transdermal drug candidates. Equally, there are also chemicals, the absorption of which in significant amounts is clearly undesirable. Compounds such as pesticides are obvious examples, but there are other materials, present perhaps as formulation excipients, that could also be detrimental. An appropriate mathematical model would allow a reliable risk assessment to be made before *in vivo* evaluations are conducted.

There are different considerations to be taken into account depending on whether the drug is to be delivered for local action or for systemic action. Since this book concerns primarily transdermal delivery, the major emphasis will be how to ensure the transport of drug through the skin into the underlying dermal vasculature and hence the systemic circulation. For a drug to be administered transdermally, it has to be very potent, as it is unlikely that more than a few tens of milligrams per day can be delivered. To a first approximation, feasibility can be assessed from the daily dose. But, as will be seen, even for a compound like nitroglycerine, which has ideal physicochemical properties for transdermal delivery from a reasonable patch area, no more than 40 to 50 mg per day can be delivered.

In some ways, it is more difficult to assess the feasibility of topical drug delivery, as the levels required in the skin for therapeutic effect are usually unknown. For transdermal delivery, there is a well-documented and determinable end point, the plasma level required for efficacious therapy. Advances in noninvasive monitoring and microdialysis can be helpful in determining the target skin concentration for topical therapy, but data are limited, and the reliability of the methodologies involved is still in question, as the techniques remain in very much a developmental stage.

Validated mathematical models represent an economically advantageous approach for the assessment of skin permeation, and their use is recommended before full-blown *in vitro* and *in vivo* experiments are conducted. The purpose of this chapter is to examine the limitations of mathematical modeling and to consider appropriate *in vitro* models prior to full clinical testing.

## II. FICK'S LAWS OF DIFFUSION

Considering that the skin is such a heterogeneous membrane, it is surprising that simple diffusion laws can be used to describe the percutaneous absorption process (3). Since transdermal delivery involves the application of a device over a long period of time, it is generally assumed that steady-state conditions have been reached and that the most relevant law of diffusion is therefore Fick's first law. The second law describes non-steady state diffusion and can be used to analyze

the rates of release from matrix type transdermal patches, to evaluate the lag phase prior to the establishment of steady-state conditions, and to describe concentration profiles across the skin as they evolve towards linearity.

The most quoted form of Fick's first law of diffusion describes steady-state diffusion through a membrane:

$$J = \frac{KD}{h} (c_o - c_i) \quad (1)$$

where  $J$  is the flux per unit area,  $K$  is the stratum corneum-formulation partition coefficient of the drug, and  $D$  is its diffusion coefficient in the stratum corneum of path length  $h$ ;  $c_o$  is the concentration of drug applied to the skin surface, and  $c_i$  is the concentration inside the skin. In most practical situations,  $c_o \gg c_i$ , and Eq. (1) simplifies to

$$J = k_p c_o \quad (2)$$

where  $k_p (= DK/h)$  is the permeability coefficient, which has units of velocity (often quoted as  $\text{cm h}^{-1}$ ), i.e., it is a heterogeneous rate constant and encodes both partition and diffusional characteristics. The input rate of the drug into the systemic circulation, from a patch of area  $A$ , is therefore given by the product

$$\text{Input rate} = A \times k_p \times c_o \quad (3)$$

The output or elimination rate from the systemic circulation equals the clearance ( $Cl$ ) multiplied by the plasma concentration at steady state ( $c_{p,ss}$ )

$$\text{Output rate} = Cl \times c_{p,ss} \quad (4)$$

Hence Eqs. (3) and (4) may be combined to predict the drug's plasma concentration following transdermal delivery:

$$c_{p,ss} = \frac{A k_p c_o}{Cl} \quad (5)$$

The plasma concentration achieved therefore depends directly on the area of the device, the skin permeability, and the applied concentration and is inversely related to the drug's clearance (4).

For a given drug, the clearance and the target plasma level are likely to be known, so to examine the feasibility of delivery, one needs the drug's skin permeability and its solubility, as this will give an indication of the maximum concentration that can be applied. These parameters can be estimated from basic physicochemical properties, which are typically measured during preformulation.

Over t  
(e.g., F  
from a  
other v  
the bar  
Guy to  
tics of t  
lar wei

1.

If log  
by con  
and ac

E  
wherea  
best ab  
often g  
coeffic  
ery. Ra  
coeffic  
sion c  
achiev  
this va  
mated

1.

where  
 $mp$  is in  
It is in  
increas  
reflecti  
be esti  
employ  
coeffic  
the dr  
in Fig.